Johnson & Johnson (JNJ): Price and Financial Metrics
JNJ Price/Volume Stats
Current price | $156.76 | 52-week high | $175.97 |
Prev. close | $158.18 | 52-week low | $144.95 |
Day low | $156.50 | Volume | 6,602,200 |
Day high | $158.69 | Avg. volume | 7,186,756 |
50-day MA | $159.56 | Dividend yield | 2.99% |
200-day MA | $159.55 | Market Cap | 377.76B |
JNJ Stock Price Chart Interactive Chart >
JNJ POWR Grades
- Quality is the dimension where JNJ ranks best; there it ranks ahead of 92.7% of US stocks.
- JNJ's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
- JNJ ranks lowest in Momentum; there it ranks in the 6th percentile.
JNJ Stock Summary
- JOHNSON & JOHNSON's market capitalization of $387,499,639,461 is ahead of 99.58% of US-listed equities.
- JNJ's went public 38.03 years ago, making it older than 92.92% of listed US stocks we're tracking.
- The volatility of JOHNSON & JOHNSON's share price is greater than that of merely 2.23% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to JOHNSON & JOHNSON are ABBV, ADBE, XOM, MA, and V.
- Visit JNJ's SEC page to see the company's official filings. To visit the company's web site, go to www.jnj.com.
JNJ Valuation Summary
- JNJ's EV/EBIT ratio is 10.2; this is 30.14% lower than that of the median Healthcare stock.
- Over the past 243 months, JNJ's price/sales ratio has gone up 0.2.
Below are key valuation metrics over time for JNJ.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
JNJ | 2023-12-29 | 4.0 | 5.3 | 10.9 | 10.2 |
JNJ | 2023-12-28 | 4.0 | 5.3 | 10.9 | 10.2 |
JNJ | 2023-12-27 | 3.9 | 5.3 | 10.9 | 10.1 |
JNJ | 2023-12-26 | 3.9 | 5.3 | 10.9 | 10.1 |
JNJ | 2023-12-22 | 3.9 | 5.3 | 10.8 | 10.1 |
JNJ | 2023-12-21 | 3.9 | 5.2 | 10.8 | 10.1 |
JNJ Growth Metrics
- The 2 year net income to common stockholders growth rate now stands at 15.52%.
- Its year over year net income to common stockholders growth rate is now at 31.19%.
- Its 2 year cash and equivalents growth rate is now at -32.63%.
The table below shows JNJ's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 94,943 | 21,194 | 17,941 |
2022-09-30 | 96,041 | 21,576 | 19,157 |
2022-06-30 | 95,588 | 23,582 | 18,366 |
2022-03-31 | 94,880 | 23,315 | 19,830 |
2021-12-31 | 93,775 | 23,410 | 20,878 |
2021-09-30 | 91,446 | 26,021 | 17,880 |
JNJ's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- JNJ has a Quality Grade of B, ranking ahead of 92.45% of graded US stocks.
- JNJ's asset turnover comes in at 0.52 -- ranking 78th of 682 Pharmaceutical Products stocks.
- CBIO, CLSD, and ABBV are the stocks whose asset turnover ratios are most correlated with JNJ.
The table below shows JNJ's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-10-03 | 0.520 | 0.675 | 0.295 |
2021-07-04 | 0.514 | 0.670 | 0.302 |
2021-04-04 | 0.498 | 0.662 | 0.273 |
2021-01-03 | 0.501 | 0.656 | 0.272 |
2020-09-27 | 0.504 | 0.657 | 0.332 |
2020-06-28 | 0.514 | 0.657 | 0.307 |
JNJ Price Target
For more insight on analysts targets of JNJ, see our JNJ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $187.95 | Average Broker Recommendation | 1.53 (Moderate Buy) |
Johnson & Johnson (JNJ) Company Bio
Founded in 1886, Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture, and sale of products in the healthcare field within its Consumer, Pharmaceutical and Medical Devices segments. The Consumer segment consists of skin and self-care product brand names such as Aveeno, Neutrogena, Rogaine, Tylenol, Motrin, Listerine, and Band-Aid. Johnson’s Pharmaceutical segment contains biopharma products that address immune, cardiovascular, metabolic, and infectious disease medical conditions. The Medical Device segment develops products centered around orthopedic, surgical, intervention, and vision solutions. The company has over 130,000 employees worldwide and is headquartered in New Brunswick, New Jersey. The company’s current Chief Executive Officer is Alex Gorsky.
Latest JNJ News From Around the Web
Below are the latest news stories about JOHNSON & JOHNSON that investors may wish to consider to help them evaluate JNJ as an investment opportunity.
2024’s Blue-Chip Winners: Top 3 Stocks for Rock-Solid ReturnsSome blue-chip stocks are poised to outperform others this year, so consider adding these to your portfolio. |
Legacy Investments: 7 Stocks to Make Your Grandkids MillionairesIf you believe in long-term investing like me, you will look for stocks that have a strong performance history and an ability to thrive in uncertain situations. |
Disaster-Proof Dividends: 3 Stocks with Resilient Payouts in Tough TimesEnjoy steady passive income and capital growth in your portfolio through these three dividend stocks with steady payouts. |
Safe Havens: 3 Fixed-Income Securities for a Balanced Portfolio in 2024If you are looking for safe havens to turn to in 2024 then you should consider adding these investments to your portfolio. |
11 Set-It-and-Forget-It Stocks to Buy According to Financial MediaIn this article, we discuss the 11 set-it-and-forget-it stocks to buy according to financial media. To skip the overview of set-it-and-forget-it stocks and portfolios, go directly to the 5 Set-It-and-Forget-It Stocks to Buy According to Financial Media. Some stocks are meant to be kept forever according to financial media and investors. The set-it-and-forget-it stock portfolio […] |
JNJ Price Returns
1-mo | 0.13% |
3-mo | 3.05% |
6-mo | -1.51% |
1-year | 5.00% |
3-year | 6.33% |
5-year | 30.09% |
YTD | 0.77% |
2023 | -8.58% |
2022 | 5.97% |
2021 | 11.44% |
2020 | 10.82% |
2019 | 16.22% |
JNJ Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Continue Researching JNJ
Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...